Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New MRI technique aims to stop breathing and heartbeats from blurring scans

NCT ID NCT05261633

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new type of MRI scan that tries to reduce blurring caused by breathing, heartbeats, and other movements in the abdomen. Researchers will compare the new method to standard scans in 80 healthy volunteers and patients with liver metastases. The goal is to see if the new approach produces clearer, more reliable images for detecting cancer and other diseases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diffusion-weighted magnetic resonance imaging (DW-MRI) device
What this could lead to
If successful, this could lead to clearer, more reliable abdominal MRI scans for detecting and monitoring cancers and organ fibrosis without radiation or contrast dyes.
What could go wrong
This is an early-stage imaging study with only 80 participants, so results may not apply to all patients or scanners. The new method may not significantly improve image quality in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

17 people

The number who actually took part.

Started

Nov 2023

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers and people with known liver metastases that are 18 years or older.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Healthy Volunteers: * 18 years of age or older Exclusion Criteria for Healthy Volunteers: * Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc) * Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening) Inclusion Criteria for Patients: * 18 years of age or older * Patients with at least one of the following: * Radiologically visible solid tumor liver metastasis, with at least one metastatic liver lesion must be a minimum of 8 mm in longest diameter * Patients presenting for liver lesion biopsy Exclusion Criteria for Patients: * Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc) * Patients with known contraindication to GBCA such as severe kidney disease or previously documented GFR \< 30 ml/min/1.73 m2 * Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met: * The subject has their own prescription for the medication. * The informed consent process is conducted prior to the self-administration of this medication * They come to the research visit with a driver * Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening) * Stent in bile ducts * Partial hepatectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal imaging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin, 53792, United States